Vitamin D Supplementation in Childhood Atopic Dermatitis

Randomized Trial of Vitamin D Supplementation in Winter-related, Childhood Atopic Dermatitis

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00879424

Enrollment

107

Registered

2009-04-10

Start date

2009-02-28

Completion date

2009-05-31

Last updated

2016-12-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic Dermatitis

Keywords

vitamin D, atopic dermatitis, eczema, winter

Brief summary

The goal of this clinical trial is to investigate the therapeutic role of vitamin D supplementation in a subset of patients with atopic dermatitis (AD): children with disease onset or worsening in the winter. The investigators hypothesis is that (1) vitamin D supplementation in patients with either wintertime onset or exacerbation of AD will improve Eczema Area and Severity Index (EASI) scores, and (2) vitamin D supplementation will improve the Investigator's Global Assessment.

Interventions

DIETARY_SUPPLEMENTcholecalciferol (vitamin D)

1000 IU once daily x 1 month Experimental group will receive Ddrops (Toronto, Canada). Placebo group will receive placebo drops.

DIETARY_SUPPLEMENTPlacebo

1000 IU once daily x 1 month Experimental group will receive Ddrops (Toronto, Canada). Placebo group will receive placebo drops.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

2 Years to 17 Years

Healthy volunteers

Inclusion criteria

* Age 2-17 years * AD rated 10-72 by EASI scale * Wintertime onset or exacerbation of AD

Exclusion criteria

* Active skin infection * History of summertime onset or exacerbation of AD * History of underlying illness causing immunosuppression within the past 2 years (eg. hematologic malignancies) * Medications causing iatrogenic immunosuppression (eg. cyclosporine; azathioprine, oral steroids) taken within the past month * Parathyroid disease * Acute or chronic renal disease * Hypercalcemia or hypocalcemia * Thyroid disease * History of osteomalacia or Paget's disease of bone * History of malabsorption (eg cystic fibrosis) * Planned trip to sunny climate during the one-month study

Design outcomes

Primary

Measure	Time frame
EASI score	1 month
Investigator Global Assessment (IGA)	1 month

Countries

Mongolia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 19, 2026